Actuarial survival from relapse according to the cumulative number of adverse features in treatment groups.

Adverse features include interval from diagnosis to transplant 2 years or more, volunteer unrelated donor, transplant not in first chronic phase, relapse within 1 year from transplant, and advanced phase at relapse. (A) Chemotherapy alone; (B) α-interferon ± chemotherapy; (C) donor lymphocyte infusion ± other (11 patients were treated with donor lymphocyte infusion followed by a second SCT); (D) second transplant ± α-interferon ± chemotherapy.